The short version of Pharmacokinetics fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-03. Anything still debated is marked as such rather than presented as settled.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
==== Dirty bulking ==== "Dirty bulking" is the process of eating at a massive caloric surplus without trying to figure out the exact amount of ingested macronutrients, often done with junk food such as burgers and fries. Weightlifters who attempt to gain mass quickly with no aesthetic concerns often choose to do this. "Dirty bulking" is often favored by bodybuilders in the off-season who are looking to rapidly increase size and strength without worrying about fat gain. While it can lead to quick weight gain and increased muscle mass due to the abundance of calories, it also typically results in a significant increase in body fat. This means a more aggressive cutting phase is usually required afterward to shed the excess fat, which can be physically and mentally taxing. Additionally, consuming large amounts of processed foods high in sugar and unhealthy fats can negatively impact cardiovascular health and insulin sensitivity over time. Despite these risks, some lifters find dirty bulking psychologically easier, as it removes the pressure of strict meal planning and food tracking.
=== March 2008 === The free fall of the SENSEX accelerated in March 2008. The month started out with the Sensex losing 900.84 points on 3 March 2008, on concerns emanating from growing credit losses in US. This would be the first of four one-day falls of greater than 700 points during the month. On 13 March 2008, the SENSEX plummeted another 770.63 points on global economic jitters.
Sulfur deposits in Sicily were the dominant source for more than a century. By the late 18th century, about 2,000 tonnes per year of sulfur were imported into Marseille, France, for the production of sulfuric acid for use in the Leblanc process. In industrializing Britain, with the repeal of tariffs on salt in 1824, demand for sulfur from Sicily surged. The increasing British control and exploitation of the mining, refining, and transportation of sulfur, coupled with the failure of this lucrative export to transform Sicily's backward and impoverished economy, led to the Sulfur Crisis of 1840, when King Ferdinand II gave a monopoly of the sulfur industry to a French firm, violating an earlier 1816 trade agreement with Britain. A peaceful solution was eventually negotiated by France. In 1867, elemental sulfur was discovered in underground deposits in Louisiana and Texas. The highly successful Frasch process was developed to extract this resource, and the United States replaced Sicily as the main producer of sulfur worldwide in the early 20th century. Since the advent of the contact process, the majority of sulfur is used to make sulfuric acid for a wide range of uses, particularly fertilizer. In recent times, the main source of sulfur has become petroleum and natural gas. This is due to the requirement to remove sulfur from fuels in order to prevent acid rain, and has resulted in a surplus of sulfur.
Sources: en.wikipedia.org
==== Danish ==== Danish Brotherhood in America Danish Sisterhood - Founded December 15, 1883, in Negaunee, Michigan, by Mrs. Christine Hemmingsen. A supreme lodge was formed in 1887, and all the officers were women by 1910. Membership was open to women of Danish descent or married to a man of Danish descent. Admission is by black ball, with one blackball enough to disqualify; there is always a second ballot; if there is another blackball a selected secret committee is appointed to determine the cause. Had a secret ritual, and no uninitiated person may attend secret meetings of the lodge. Locals are called "lodges"; regional groups are called "Districts". National convention meets quadrennially. Supreme Lodge headquarters is in Chicago. Provides funeral benefits of up to $1,000, no more than two beneficiaries can be designated, and in special circumstances, other benefits can be applied for. Membership in 1922, 8,000, 1934, 7,000, and 1979, 4,500.
=== Drug interactions === Flucloxacillin can reduce the excretion of methotrexate, potentially resulting in a risk of methotrexate toxicity. The level of flucloxacillin in the blood may rise in kidney failure and with the use of probenecid.
=== Advantages === Advantages include low fragmentation: only a small amount of energy is transferred during the ionization process (compared to e.g. electron ionization), therefore fragmentation is suppressed and the obtained mass spectra are easily interpretable. No sample preparation is necessary: VOC-containing air and headspaces over liquids can be analyzed directly, in real time. A typical response time of 100 ms enables online monitoring. Absolute concentrations are obtained directly without previous calibration measurements. Due to the simple design and the low number of parts needed for a PTR-MS instrument, it can be built in into space saving and even mobile housings. PTR-MS operation requires only electric power and a small amount of distilled water. Unlike other techniques, no gas cylinders are needed for buffer gas or calibration standards.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.